|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
SI1523496T1
(sl)
|
2002-07-18 |
2011-11-30 |
Merus B V |
Rekombinantno proizvajanje zmesi protiteles
|
|
US8597911B2
(en)
*
|
2003-06-11 |
2013-12-03 |
Chugai Seiyaku Kabushiki Kaisha |
Process for producing antibodies
|
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
|
HUE026303T2
(hu)
|
2005-07-25 |
2016-06-28 |
Emergent Product Dev Seattle |
B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
|
|
WO2007110205A2
(en)
*
|
2006-03-24 |
2007-10-04 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
|
DK2006381T3
(en)
*
|
2006-03-31 |
2016-02-22 |
Chugai Pharmaceutical Co Ltd |
PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
|
|
EP2009101B1
(en)
*
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
MY150756A
(en)
*
|
2006-08-21 |
2014-02-28 |
Hoffmann La Roche |
Tumor theraphy with an anti-vegf antibody
|
|
US7750124B2
(en)
|
2006-09-29 |
2010-07-06 |
Oncomed Pharmaceuticals, Inc. |
Anti-human DLL4 antibodies and compositions
|
|
KR20100089816A
(ko)
*
|
2007-08-21 |
2010-08-12 |
모르포시스 아게 |
이황화 결합을 형성하기 위한 개선된 방법
|
|
ES2687808T3
(es)
|
2007-09-26 |
2018-10-29 |
Chugai Seiyaku Kabushiki Kaisha |
Región constante de anticuerpo modificado
|
|
DK2202245T3
(en)
*
|
2007-09-26 |
2016-11-21 |
Chugai Pharmaceutical Co Ltd |
A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
|
|
EP2080770A1
(en)
*
|
2008-01-21 |
2009-07-22 |
MorphoSys AG |
Proteinaceous binding molecules comprising purification tags
|
|
AU2009234277B2
(en)
|
2008-04-11 |
2014-12-04 |
Aptevo Research And Development Llc |
CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
US8298533B2
(en)
|
2008-11-07 |
2012-10-30 |
Medimmune Limited |
Antibodies to IL-1R1
|
|
WO2010107110A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
TWI646193B
(zh)
|
2009-03-19 |
2019-01-01 |
中外製藥股份有限公司 |
抗體恆定區域改變體
|
|
CN102459346B
(zh)
|
2009-04-27 |
2016-10-26 |
昂考梅德药品有限公司 |
制造异源多聚体分子的方法
|
|
EP2480661A1
(en)
|
2009-09-24 |
2012-08-01 |
UCB Pharma, S.A. |
Bacterial host strain
|
|
JP5837821B2
(ja)
|
2009-09-24 |
2015-12-24 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
EP3485908B1
(en)
|
2009-10-16 |
2021-08-18 |
Mereo BioPharma 5, Inc. |
Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
|
|
GB201000590D0
(en)
*
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial host strain
|
|
GB201000591D0
(en)
*
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial hoist strain
|
|
GB201000587D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial hoist strain
|
|
EP2533811A4
(en)
*
|
2010-02-12 |
2013-12-25 |
Res Corp Technologies Inc |
MULTIMETER PROTEINS WITH IMMUNE LOBULIN CONSTANTS DOMAINS
|
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
DK2560683T4
(da)
|
2010-04-23 |
2022-08-29 |
Hoffmann La Roche |
Fremstilling af heteromultimeriske proteiner
|
|
GB201012599D0
(en)
|
2010-07-27 |
2010-09-08 |
Ucb Pharma Sa |
Process for purifying proteins
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
TR201802772T4
(tr)
|
2010-11-17 |
2018-03-21 |
Chugai Pharmaceutical Co Ltd |
Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
|
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
|
LT2647707T
(lt)
|
2010-11-30 |
2018-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Citotoksiškumą indukuojantis terapinis agentas
|
|
JP6161540B2
(ja)
|
2011-02-04 |
2017-07-12 |
ジェネンテック， インコーポレイテッド |
Ｆｃ変異体及びそれらの生産方法
|
|
US10689447B2
(en)
*
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
CN106432506A
(zh)
|
2011-05-24 |
2017-02-22 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
|
MX348738B
(es)
*
|
2011-07-13 |
2017-06-27 |
Ucb Pharma Sa |
Cepa huesped bacteriana que expresa dsbc recombinante.
|
|
HRP20190044T1
(hr)
|
2011-09-23 |
2019-02-22 |
Oncomed Pharmaceuticals, Inc. |
Agensi koji vežu vegf/dll4 i njihove uporabe
|
|
ES2971444T3
(es)
*
|
2011-10-11 |
2024-06-05 |
F Hoffmann Lar Roche Ag |
Ensamblaje mejorado de anticuerpos biespecíficos
|
|
US11851476B2
(en)
|
2011-10-31 |
2023-12-26 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
|
ES2743399T3
(es)
|
2012-04-20 |
2020-02-19 |
Merus Nv |
Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
|
|
GB201208367D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Biological product
|
|
US10358492B2
(en)
|
2012-09-27 |
2019-07-23 |
Merus N.V. |
Bispecific IgG antibodies as T cell engagers
|
|
AU2013337811A1
(en)
|
2012-10-31 |
2015-05-14 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a DLL4 antagonist
|
|
AU2013342163B2
(en)
|
2012-11-08 |
2018-08-16 |
F. Hoffmann-La Roche Ltd |
IL-6 antagonists and uses thereof
|
|
WO2014078729A1
(en)
|
2012-11-15 |
2014-05-22 |
Genentech, Inc. |
IONIC STRENGTH-MEDIATED pH GRADIENT ION EXCHANGE CHROMATOGRAPHY
|
|
PL2922872T3
(pl)
|
2012-11-21 |
2019-03-29 |
Janssen Biotech, Inc. |
Bispecyficzne przeciwciała przeciwko egfr/c-met
|
|
US20170275367A1
(en)
|
2012-11-21 |
2017-09-28 |
Janssen Biotech, Inc. |
Bispecific EGFR/C-Met Antibodies
|
|
EP3424530A1
(en)
|
2013-03-15 |
2019-01-09 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
KR20250152665A
(ko)
*
|
2013-07-31 |
2025-10-23 |
암젠 인크 |
Ｆc-함유 폴리펩타이드의 안정화
|
|
ES2881306T3
(es)
|
2013-09-27 |
2021-11-29 |
Chugai Pharmaceutical Co Ltd |
Método para la producción de heteromultímeros de polipéptidos
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
SI3110849T1
(sl)
|
2014-02-28 |
2021-01-29 |
Merus N.V. |
Protitelo, ki veže ERBB-2 in ERBB-3
|
|
SG11201607109QA
(en)
|
2014-02-28 |
2016-09-29 |
Merus Nv |
Antibodies that bind egfr and erbb3
|
|
ME03558B
(me)
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
ES2955736T3
(es)
|
2014-05-06 |
2023-12-05 |
Hoffmann La Roche |
Producción de proteínas heteromultiméricas usando células de mamífero
|
|
US9884921B2
(en)
|
2014-07-01 |
2018-02-06 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
BR112017001242A2
(pt)
|
2014-07-21 |
2017-12-05 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico a cd33
|
|
WO2016014565A2
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
|
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
RS60305B1
(sr)
|
2014-09-05 |
2020-07-31 |
Janssen Pharmaceutica Nv |
Agensi koji vezuju cd123 i njihove upotrebe
|
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
MX389663B
(es)
|
2014-10-14 |
2025-03-20 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
|
|
MX382902B
(es)
|
2014-10-31 |
2025-03-13 |
Oncomed Pharm Inc |
Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
|
|
US10112994B2
(en)
|
2014-11-05 |
2018-10-30 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
|
EP3215525B1
(en)
*
|
2014-11-05 |
2020-07-29 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
|
DK4268843T3
(da)
|
2014-11-07 |
2025-11-10 |
F Hoffmann La Roche Ltd |
Forbedrede IL-6-antistoffer
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
WO2016159213A1
(ja)
*
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
IL254817B2
(en)
|
2015-04-08 |
2023-12-01 |
Novartis Ag |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CA2985125A1
(en)
|
2015-05-06 |
2016-11-10 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
|
EP3345928B1
(en)
|
2015-07-10 |
2020-06-24 |
Merus N.V. |
Human cd3 binding antibody
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
PT3337824T
(pt)
|
2015-08-17 |
2020-09-10 |
Janssen Pharmaceutica Nv |
Anticorpos anti-bcma, moléculas de ligação a antigénio biespecíficas que ligam bcma e cd3, e suas utilizações
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
WO2017053705A1
(en)
|
2015-09-23 |
2017-03-30 |
Oncomed Pharmaceuticals, Inc. |
Methods and compositions for treatment of cancer
|
|
MX2018003905A
(es)
|
2015-09-30 |
2018-09-06 |
Janssen Biotech Inc |
Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso.
|
|
BR112018008068A2
(en)
|
2015-10-23 |
2018-11-13 |
Merus N.V. |
binding molecules that inhibit cancer growth
|
|
EP3371220A2
(en)
|
2015-11-02 |
2018-09-12 |
Janssen Pharmaceutica NV |
Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
|
|
SI3370768T1
(sl)
|
2015-11-03 |
2022-04-29 |
Janssen Biotech, Inc. |
Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
|
|
EP3389712B1
(en)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
JP2019502695A
(ja)
|
2015-12-17 |
2019-01-31 |
ノバルティス アーゲー |
ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用
|
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
|
JP7219005B2
(ja)
|
2015-12-28 |
2023-02-07 |
中外製薬株式会社 |
Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
|
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
|
US20190046642A1
(en)
|
2016-02-23 |
2019-02-14 |
Eleven Biotherapeutics, Inc. |
Il-6 antagonist formulations and uses thereof
|
|
CA3016287A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
EP3431102A4
(en)
|
2016-03-14 |
2019-09-25 |
Chugai Seiyaku Kabushiki Kaisha |
CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
SI3443096T1
(sl)
|
2016-04-15 |
2023-07-31 |
Novartis Ag |
Sestavki in postopki za selektivno izražanje himerni antigenskih receptorjev
|
|
JP7320943B2
(ja)
|
2016-04-28 |
2023-08-04 |
中外製薬株式会社 |
抗体含有製剤
|
|
EP3464375A2
(en)
|
2016-06-02 |
2019-04-10 |
Novartis AG |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
CN120285179A
(zh)
|
2016-07-15 |
2025-07-11 |
诺华股份有限公司 |
使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
|
|
TWI781108B
(zh)
|
2016-07-20 |
2022-10-21 |
比利時商健生藥品公司 |
抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
|
|
IL264486B2
(en)
|
2016-07-28 |
2025-04-01 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
|
SG11201900885VA
(en)
|
2016-08-01 |
2019-02-27 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
CN109863170B
(zh)
|
2016-08-12 |
2024-08-16 |
詹森生物科技公司 |
具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子
|
|
SG11201900744SA
(en)
|
2016-08-12 |
2019-02-27 |
Janssen Biotech Inc |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
JOP20190097A1
(ar)
|
2016-10-27 |
2019-04-28 |
Janssen Pharmaceutica Nv |
الجلوبولينات المناعية واستخداماتها
|
|
EP3551225A1
(en)
|
2016-12-07 |
2019-10-16 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
US20200048359A1
(en)
|
2017-02-28 |
2020-02-13 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
CA3058343A1
(en)
|
2017-03-31 |
2018-10-04 |
Merus N.V. |
Erbb-2 and erbb-3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
US12195551B2
(en)
|
2017-05-17 |
2025-01-14 |
Merus N.V. |
Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
|
|
KR102661320B1
(ko)
|
2017-06-05 |
2024-05-03 |
얀센 바이오테크 인코포레이티드 |
이중특이성 항체 생성을 위한 표면 전하 조작 방법
|
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
|
US10882907B2
(en)
|
2017-06-21 |
2021-01-05 |
Gilead Sciences, Inc. |
Multispecific antibodies that target HIV GP120 and CD3
|
|
EP3641812A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
AU2018292618A1
(en)
|
2017-06-27 |
2019-12-19 |
Novartis Ag |
Dosage regimens for anti-TIM-3 antibodies and uses thereof
|
|
EP3652209A2
(en)
|
2017-07-11 |
2020-05-20 |
Compass Therapeutics LLC |
Agonist antibodies that bind human cd137 and uses thereof
|
|
KR20250025039A
(ko)
|
2017-07-20 |
2025-02-20 |
노파르티스 아게 |
항-lag-3 항체의 투여 요법 및 그의 용도
|
|
HUE071182T2
(hu)
|
2017-08-09 |
2025-08-28 |
Merus Nv |
EGFR és CMET kötõ antitestek
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
AU2018361430B2
(en)
|
2017-11-01 |
2025-08-14 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody variant and isoform with lowered biological activity
|
|
AU2018368731A1
(en)
|
2017-11-16 |
2020-05-14 |
Novartis Ag |
Combination therapies
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
AU2019270624B2
(en)
|
2018-05-16 |
2024-05-02 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
|
|
AU2019272575A1
(en)
|
2018-05-21 |
2020-12-10 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by NK cells
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
JOP20200303A1
(ar)
|
2018-05-24 |
2020-11-23 |
Janssen Biotech Inc |
عوامل ربط psma واستخداماتها
|
|
RS66901B1
(sr)
|
2018-05-24 |
2025-07-31 |
Janssen Biotech Inc |
Anti-cd3 antitela i njihova upotreba
|
|
JOP20190116A1
(ar)
|
2018-05-24 |
2019-11-24 |
Janssen Biotech Inc |
الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
|
|
EA202092849A1
(ru)
|
2018-05-24 |
2021-03-16 |
Янссен Байотек, Инк. |
Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
|
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
TWI848951B
(zh)
|
2018-06-01 |
2024-07-21 |
瑞士商諾華公司 |
針對ｂｃｍａ之結合分子及其用途
|
|
AU2019284911A1
(en)
|
2018-06-13 |
2020-12-17 |
Novartis Ag |
BCMA chimeric antigen receptors and uses thereof
|
|
US20210238268A1
(en)
|
2018-06-19 |
2021-08-05 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
PE20210685A1
(es)
|
2018-07-03 |
2021-04-08 |
Gilead Sciences Inc |
Anticuerpos que se dirigen al gp120 de vih y metodos de uso
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
JP7529568B2
(ja)
*
|
2018-09-28 |
2024-08-06 |
協和キリン株式会社 |
抗体組成物
|
|
MX2021005594A
(es)
|
2018-11-13 |
2021-10-22 |
Compass Therapeutics Llc |
Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
|
|
JP2022513255A
(ja)
|
2018-12-20 |
2022-02-07 |
ノバルティス アーゲー |
ＨＤＭ２－ｐ５３相互作用阻害剤とＢＣＬ２阻害剤との組み合わせ及び癌を処置するためのその使用
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
AU2020208828A1
(en)
|
2019-01-15 |
2021-08-05 |
Janssen Biotech, Inc. |
Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
|
US20220064278A1
(en)
|
2019-01-23 |
2022-03-03 |
Janssen Biotech, Inc. |
Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis
|
|
ES3032659T3
(en)
|
2019-02-15 |
2025-07-23 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
ES2982474T3
(es)
|
2019-02-15 |
2024-10-16 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
EP3927747A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
CN119661722A
(zh)
|
2019-02-21 |
2025-03-21 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
US20220088075A1
(en)
|
2019-02-22 |
2022-03-24 |
The Trustees Of The University Of Pennsylvania |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
US11459391B2
(en)
|
2019-02-26 |
2022-10-04 |
Janssen Biotech, Inc. |
Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
|
|
MA55305A
(fr)
|
2019-03-11 |
2022-01-19 |
Janssen Biotech Inc |
Anticorps bispécifiques anti-v béta 17/anti-cd123
|
|
CN113825765A
(zh)
|
2019-03-14 |
2021-12-21 |
詹森生物科技公司 |
用于制备抗il12/il23抗体组合物的制造方法
|
|
CA3133388A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
|
CA3133383A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
|
MA55282A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
|
|
PH12021552414A1
(en)
|
2019-03-29 |
2022-07-25 |
Atarga Llc |
Anti fgf23 antibody
|
|
KR20220002899A
(ko)
|
2019-04-19 |
2022-01-07 |
얀센 바이오테크 인코포레이티드 |
항-psma/cd3 항체로 전립선암을 치료하는 방법
|
|
KR20220017892A
(ko)
|
2019-05-08 |
2022-02-14 |
얀센 바이오테크 인코포레이티드 |
T세포 매개 면역의 조절을 위한 물질 및 방법
|
|
JOP20210304A1
(ar)
|
2019-05-14 |
2023-01-30 |
Janssen Biotech Inc |
علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
|
|
US12037378B2
(en)
|
2019-05-21 |
2024-07-16 |
Novartis Ag |
Variant CD58 domains and uses thereof
|
|
BR112021023048A2
(pt)
|
2019-05-21 |
2022-04-19 |
Novartis Ag |
Moléculas de ligação a cd19 e usos das mesmas
|
|
CA3140142A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Trispecific binding molecules against bcma and uses thereof
|
|
TWI879770B
(zh)
|
2019-05-30 |
2025-04-11 |
美商安進公司 |
工程改造鉸鏈區以驅動抗體二聚化
|
|
WO2020245676A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
|
|
US12435131B2
(en)
|
2019-07-11 |
2025-10-07 |
Tavotek Biotherapeutics (Hong Kong) Limited |
Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
|
|
EP3997122A1
(en)
|
2019-07-12 |
2022-05-18 |
Janssen Pharmaceutica NV |
Binding agents and uses thereof
|
|
CN114585651A
(zh)
|
2019-08-08 |
2022-06-03 |
再生元制药公司 |
新型抗原结合分子形式
|
|
US20220242962A1
(en)
|
2019-08-12 |
2022-08-04 |
Aptevo Research And Development Llc |
4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
|
|
BR112022005909A2
(pt)
|
2019-09-29 |
2022-10-11 |
Jacobio Pharmaceuticals Co Ltd |
anticorpos isolados ou fragmento de ligação ao antígeno dos mesmos, método de preparação e usos dos mesmos, composição nucleotídica, vetor, célula hospedeira, composição farmacêutica, reagente para detecção de lif em amostras biológicas, e método exvivo para detectar o lif em amostras biológicas
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
CN114786680A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
Tim-3抑制剂及其用途
|
|
AU2020379735A1
(en)
|
2019-11-05 |
2022-05-26 |
Regeneron Pharmaceuticals, Inc. |
N-terminal SCFV multispecific binding molecules
|
|
CA3163104A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
US20210188990A1
(en)
|
2019-12-11 |
2021-06-24 |
Cilag Gmbh International |
Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
|
|
US20210188934A1
(en)
|
2019-12-20 |
2021-06-24 |
Regeneron Pharmaceuticals, Inc. |
Novel il2 agonists and methods of use thereof
|
|
MX2022007759A
(es)
|
2019-12-20 |
2022-07-19 |
Novartis Ag |
Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
CA3163172A1
(en)
|
2020-01-08 |
2021-07-15 |
Peter Verheesen |
Methods for treating pemphigus disorders
|
|
US20210222244A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
|
EP4090335A1
(en)
|
2020-01-17 |
2022-11-23 |
Novartis AG |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
JOP20220184A1
(ar)
|
2020-02-12 |
2023-01-30 |
Janssen Biotech Inc |
علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
|
|
BR112022016633A2
(pt)
|
2020-02-27 |
2022-12-13 |
Novartis Ag |
Métodos para produzir células que expressam receptor de antígeno quimérico
|
|
CN116249549A
(zh)
|
2020-03-27 |
2023-06-09 |
诺华股份有限公司 |
用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
|
|
CA3179369A1
(en)
*
|
2020-04-01 |
2021-10-07 |
Kyowa Kirin Co., Ltd. |
Antibody composition
|
|
CN115916840A
(zh)
|
2020-04-16 |
2023-04-04 |
詹森生物科技公司 |
用于监测多特异性分子的形成物的反相高效液相色谱（rp-hplc）的系统、材料和方法
|
|
JP2023523794A
(ja)
|
2020-05-01 |
2023-06-07 |
ノバルティス アーゲー |
人工操作免疫グロブリン
|
|
IL298046A
(en)
|
2020-05-11 |
2023-01-01 |
Janssen Biotech Inc |
Methods for treating multiple myeloma
|
|
MX2022014239A
(es)
|
2020-05-12 |
2023-02-09 |
Regeneron Pharma |
Nuevos agonistas de il10 y metodos para su uso.
|
|
KR20230017841A
(ko)
|
2020-05-27 |
2023-02-06 |
얀센 바이오테크 인코포레이티드 |
Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
|
|
GB202008860D0
(en)
|
2020-06-11 |
2020-07-29 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
|
MX2022015852A
(es)
|
2020-06-23 |
2023-01-24 |
Novartis Ag |
Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
|
PH12023550015A1
(en)
|
2020-07-16 |
2024-03-11 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
CN116322776A
(zh)
|
2020-08-03 |
2023-06-23 |
詹森生物科技公司 |
用于病毒治疗剂中的多向生物转运的材料和方法
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2022035722A1
(en)
|
2020-08-10 |
2022-02-17 |
Janssen Biotech, Inc. |
Materials and methods for producing bioengineered virus specific lymphocytes
|
|
EP4200338A1
(en)
|
2020-08-20 |
2023-06-28 |
Amgen Inc. |
Antigen binding proteins with non-canonical disulfide in fab region
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
WO2022056197A1
(en)
|
2020-09-11 |
2022-03-17 |
Janssen Biotech, Inc. |
Immune targeting molecules and uses thereof
|
|
WO2022056192A1
(en)
|
2020-09-11 |
2022-03-17 |
Janssen Biotech, Inc. |
Methods and compositions for modulating beta chain mediated immunity
|
|
WO2022072291A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Amgen Inc. |
Cation exchange chromatography process
|
|
CA3197047A1
(en)
|
2020-10-07 |
2022-04-14 |
Amgen Inc. |
Rational selection of building blocks for the assembly of multispecific antibodies
|
|
UY39467A
(es)
|
2020-10-13 |
2022-04-29 |
Janssen Biotech Inc |
Inmunidad mediada por células t de bioingeniería, materiales y otros métodos para modular el grupo de diferenciación iv y / o viii
|
|
TW202233674A
(zh)
|
2020-10-28 |
2022-09-01 |
美商健生生物科技公司 |
用於調節δγ鏈介導之免疫的組成物及方法
|
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
US20240002509A1
(en)
|
2020-11-06 |
2024-01-04 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
|
CN116390933A
(zh)
|
2020-11-06 |
2023-07-04 |
诺华股份有限公司 |
治疗b细胞恶性肿瘤的抗cd19剂和b细胞靶向剂组合疗法
|
|
TW202233663A
(zh)
|
2020-11-10 |
2022-09-01 |
美商安進公司 |
多特異性抗原結合結構域之新穎的連接子
|
|
CA3198447A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
KR20230117379A
(ko)
|
2020-12-01 |
2023-08-08 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
이종이량체 psma 및 cd3-결합 이중특이적 항체
|
|
AU2022214491A1
(en)
|
2021-01-28 |
2023-09-14 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
|
|
US20220267438A1
(en)
|
2021-02-16 |
2022-08-25 |
Janssen Pharmaceutica Nv |
Trispecific antibody targeting bcma, gprc5d, and cd3
|
|
US11639396B2
(en)
|
2021-02-16 |
2023-05-02 |
Janssen Biotech, Inc. |
Antibody binding to a linker peptide
|
|
WO2022189942A1
(en)
|
2021-03-09 |
2022-09-15 |
Janssen Biotech, Inc. |
Treatment of cancers lacking egfr-activating mutations
|
|
MX2023011267A
(es)
|
2021-03-24 |
2023-12-14 |
Janssen Biotech Inc |
Anticuerpo triespecífico dirigido a cd79b, cd20, y cd3.
|
|
CN117098781A
(zh)
|
2021-03-24 |
2023-11-21 |
詹森生物科技公司 |
靶向cd22和cd79b的抗体
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CN117597365A
(zh)
|
2021-05-04 |
2024-02-23 |
再生元制药公司 |
多特异性fgf21受体激动剂及其应用
|
|
TW202307007A
(zh)
|
2021-05-04 |
2023-02-16 |
美商再生元醫藥公司 |
多特異性fgf21受體促效劑及其等用途
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
TW202309094A
(zh)
|
2021-05-18 |
2023-03-01 |
美商健生生物科技公司 |
用於識別癌症患者以進行組合治療之方法
|
|
CR20230581A
(es)
|
2021-06-04 |
2024-02-13 |
Amgen Inc |
Anticuerpos anti-CCR8 y usos de los mismos
|
|
IL309349A
(en)
|
2021-06-14 |
2024-02-01 |
argenx BV |
Antibodies against interleukin 9 and methods of using them
|
|
WO2022266223A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
|
|
IL308134A
(en)
|
2021-06-22 |
2023-12-01 |
Novartis Ag |
BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVA
|
|
IL309997A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-TNF antibody compositions
|
|
CN117957251A
(zh)
|
2021-07-09 |
2024-04-30 |
詹森生物科技公司 |
用于制备抗tnf抗体组合物的制造方法
|
|
KR20240034215A
(ko)
|
2021-07-09 |
2024-03-13 |
얀센 바이오테크 인코포레이티드 |
항-il12/il23 항체 조성물을 생산하기 위한 제조 방법
|
|
US20250066441A1
(en)
|
2021-07-19 |
2025-02-27 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
US20250270314A1
(en)
|
2021-08-02 |
2025-08-28 |
Tavotek Biotech (Suzhou) Ltd |
Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
|
|
US20250277051A1
(en)
|
2021-08-02 |
2025-09-04 |
Hangzhou Unogen Biotech, Ltd |
Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
|
|
WO2023022965A2
(en)
|
2021-08-16 |
2023-02-23 |
Regeneron Pharmaceuticals, Inc. |
Novel il27 receptor agonists and methods of use thereof
|
|
EP4405396A2
(en)
|
2021-09-20 |
2024-07-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2023069888A1
(en)
|
2021-10-18 |
2023-04-27 |
Tavotek Biotherapeutics (Hong Kong) Limited |
ANTI-EGFR ANTIBODIES, ANTI-cMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF
|
|
CN118119642A
(zh)
|
2021-10-28 |
2024-05-31 |
诺华股份有限公司 |
工程化Fc变体
|
|
EP4426734A1
(en)
|
2021-11-01 |
2024-09-11 |
Janssen Biotech, Inc. |
Compositions and methods for the modulation of beta chain-mediated immunity
|
|
AU2022380722A1
(en)
|
2021-11-03 |
2024-06-20 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
|
|
TW202334223A
(zh)
|
2021-11-11 |
2023-09-01 |
美商再生元醫藥公司 |
Ｃｄ２０－ｐｄ１結合分子及其使用方法
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
US20230183360A1
(en)
|
2021-12-09 |
2023-06-15 |
Janssen Biotech, Inc. |
Use of Amivantamab to Treat Colorectal Cancer
|
|
WO2023139293A1
(en)
|
2022-01-24 |
2023-07-27 |
Novimmune Sa |
Composition and methods for the selective activation of cytokine signaling pathways
|
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
|
TW202342057A
(zh)
|
2022-02-07 |
2023-11-01 |
美商健生生物科技公司 |
用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
|
|
EP4490192A1
(en)
|
2022-03-07 |
2025-01-15 |
Novimmune S.A. |
Cd28 bispecific antibodies for targeted t cell activation
|
|
US12122850B2
(en)
|
2022-03-14 |
2024-10-22 |
LamKap Bio gamma AG |
Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
|
|
TW202346337A
(zh)
|
2022-03-29 |
2023-12-01 |
美商恩格姆生物製藥公司 |
Ilt3及cd3結合劑以及其使用方法
|
|
AR129136A1
(es)
|
2022-04-26 |
2024-07-17 |
Novartis Ag |
Anticuerpos multiespecíficos que se dirigen a il-13 e il-18
|
|
CN119546628A
(zh)
|
2022-05-11 |
2025-02-28 |
再生元制药公司 |
多特异性结合分子前蛋白及其用途
|
|
EP4522757A2
(en)
|
2022-05-13 |
2025-03-19 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2023230594A1
(en)
|
2022-05-27 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
WO2023235848A1
(en)
|
2022-06-04 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
CN119630697A
(zh)
|
2022-06-15 |
2025-03-14 |
阿根思有限公司 |
Ph依赖性hsa结合分子及使用方法
|
|
JP2025522814A
(ja)
|
2022-06-30 |
2025-07-17 |
ヤンセン バイオテツク，インコーポレーテツド |
胃癌又は食道癌を治療するための抗ｅｇｆｒ／抗ｍｅｔ抗体の使用
|
|
MA71622A
(fr)
|
2022-07-29 |
2025-05-30 |
Alector Llc |
Domaines de liaison à l'antigène cd98hc et leurs utilisations
|
|
EP4562044A2
(en)
|
2022-07-29 |
2025-06-04 |
Alector LLC |
Transferrin receptor antigen-binding domains and uses therefor
|
|
TW202435912A
(zh)
|
2022-08-03 |
2024-09-16 |
美商航海家醫療公司 |
用於穿過血腦屏障之組合物及方法
|
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
|
EP4573110A1
(en)
|
2022-08-18 |
2025-06-25 |
Regeneron Pharmaceuticals, Inc. |
Interferon proproteins and uses thereof
|
|
CN120476144A
(zh)
|
2022-10-21 |
2025-08-12 |
诺夫免疫股份有限公司 |
用于免疫检查点依赖性T细胞活化的PD-L1xCD28双特异性抗体
|
|
KR20250093319A
(ko)
|
2022-10-24 |
2025-06-24 |
에프. 호프만-라 로슈 아게 |
Il-6 길항제에 대한 반응 예측
|
|
WO2024089551A1
(en)
|
2022-10-25 |
2024-05-02 |
Janssen Biotech, Inc. |
Msln and cd3 binding agents and methods of use thereof
|
|
AU2023395983A1
(en)
|
2022-12-16 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses
|
|
EP4638729A1
(en)
|
2022-12-23 |
2025-10-29 |
Regeneron Pharmaceuticals, Inc. |
Ace2 fusion proteins and uses thereof
|
|
EP4649092A1
(en)
|
2023-01-13 |
2025-11-19 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2024151978A1
(en)
|
2023-01-13 |
2024-07-18 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
AU2024217296A1
(en)
|
2023-02-09 |
2025-09-25 |
Janssen Biotech, Inc. |
Anti-v beta 17/anti-cd123 bispecific antibodies
|
|
IL322940A
(en)
|
2023-02-28 |
2025-10-01 |
Regeneron Pharma |
Multivalent anti-spike protein binding molecules and their uses
|
|
IL322890A
(en)
|
2023-02-28 |
2025-10-01 |
Regeneron Pharma |
Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
|
|
WO2024189544A1
(en)
|
2023-03-13 |
2024-09-19 |
Janssen Biotech, Inc. |
Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies
|
|
AU2024240129A1
(en)
|
2023-03-17 |
2025-10-09 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
AU2024269008A1
(en)
|
2023-05-10 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
WO2024238415A1
(en)
|
2023-05-12 |
2024-11-21 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor antagonists and uses thereof
|
|
CA3228195A1
(en)
|
2023-05-23 |
2025-06-30 |
Janssen Biotech Inc |
Methods for treatment of non-small cell lung cancer (nsclc)
|
|
US20250011449A1
(en)
|
2023-06-11 |
2025-01-09 |
Regeneron Pharmaceuticals, Inc. |
Circularized antibody molecules
|
|
US20250136688A1
(en)
|
2023-08-07 |
2025-05-01 |
Janssen Biotech, Inc. |
Stabilized cd3 antigen binding agents and methods of use thereof
|
|
WO2025032508A1
(en)
|
2023-08-07 |
2025-02-13 |
Janssen Biotech, Inc. |
Enpp3 and cd3 binding agents and methods of use thereof
|
|
WO2025038600A1
(en)
|
2023-08-14 |
2025-02-20 |
Amgen Inc. |
Methods for reducing yellow color
|
|
EP4630457A1
(en)
|
2023-08-18 |
2025-10-15 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules and uses thereof
|
|
AR133647A1
(es)
|
2023-08-25 |
2025-10-22 |
Proteologix Us Inc |
Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
|
|
AR133648A1
(es)
|
2023-08-25 |
2025-10-22 |
Proteologix Us Inc |
Constructos de anticuerpos anti-tslp y sus usos
|
|
WO2025052273A1
(en)
|
2023-09-05 |
2025-03-13 |
Janssen Biotech, Inc. |
Methods of treating non-small cell lung cancer
|
|
WO2025051895A1
(en)
|
2023-09-06 |
2025-03-13 |
Novimmune Sa |
Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
|
|
US20250101111A1
(en)
|
2023-09-07 |
2025-03-27 |
argenx BV |
Fcrn antagonists and methods of use
|
|
WO2025068957A1
(en)
|
2023-09-29 |
2025-04-03 |
Novartis Ag |
Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations
|
|
WO2025079020A1
(en)
|
2023-10-12 |
2025-04-17 |
Janssen Biotech, Inc. |
First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
|
|
WO2025085610A1
(en)
|
2023-10-18 |
2025-04-24 |
Janssen Biotech, Inc. |
Combination treatment of prostate cancers with two bispecific antibodies
|
|
TW202535406A
(zh)
|
2023-10-30 |
2025-09-16 |
美商壯生和壯生企業創新公司 |
用於治療肺癌之a2a受體拮抗劑
|
|
WO2025106469A1
(en)
|
2023-11-14 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Engineered heavy chain variable domains and uses thereof
|
|
WO2025122614A1
(en)
|
2023-12-05 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Il18 receptor agonists and methods of use thereof
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025120583A2
(en)
|
2023-12-08 |
2025-06-12 |
Janssen Biotech, Inc. |
CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF
|
|
WO2025126102A1
(en)
|
2023-12-12 |
2025-06-19 |
Janssen Biotech, Inc. |
Enpp3 × cd3 bispecific antibodies and use thereof
|
|
WO2025133707A1
(en)
|
2023-12-19 |
2025-06-26 |
Vectory Therapeutics B.V. |
Anti-tdp-43 antibodies and uses thereof
|
|
WO2025133694A1
(en)
|
2023-12-20 |
2025-06-26 |
argenx BV |
Fcrn/hsa-binding molecules and methods of use
|
|
GB202319605D0
(en)
|
2023-12-20 |
2024-01-31 |
argenx BV |
Monovalent binding molecules and methods of use
|
|
WO2025134050A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
|
|
WO2025134049A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
|
|
WO2025153988A1
(en)
|
2024-01-16 |
2025-07-24 |
Janssen Biotech, Inc. |
Use of amivantamab to treat colorectal cancer
|
|
WO2025158277A1
(en)
|
2024-01-22 |
2025-07-31 |
Janssen Biotech, Inc. |
Use of amivantamab to treat head and neck cancer
|
|
WO2025166042A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
WO2025166045A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
|
|
WO2025166077A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Compositions comprising progranulin and uses thereof
|
|
WO2025166040A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
|
|
WO2025191459A1
(en)
|
2024-03-11 |
2025-09-18 |
Janssen Biotech, Inc. |
Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
|
|
WO2025199243A1
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Trivalent multispecific binding molecules and methods of use thereof
|
|
WO2025221736A2
(en)
|
2024-04-15 |
2025-10-23 |
Janssen Biotech, Inc. |
Ltbr binding molecules and uses thereof
|
|
WO2025226541A2
(en)
|
2024-04-26 |
2025-10-30 |
Janssen Biotech, Inc. |
Klk2xcd3 antibody and an anti-cancer agent for treating prostate cancer
|
|
WO2025229224A1
(en)
|
2024-05-03 |
2025-11-06 |
argenx BV |
Monovalent anti-iga binding molecules and methods of use
|
|
WO2025233825A1
(en)
|
2024-05-06 |
2025-11-13 |
Janssen Pharmaceutica Nv |
Enrichment of cells expressing a bird linker
|
|
WO2025240335A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2025245494A1
(en)
|
2024-05-24 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il12 receptor agonists
|
|
WO2025243243A1
(en)
|
2024-05-24 |
2025-11-27 |
Janssen Biotech, Inc. |
Bispecific antibody targeting emr2 (cd312) and the t-cell receptor trbv19
|